Caris Life Sciences Seeks Approval for Advanced Blood Testing in New York State

Caris Life Sciences®, a prominent player in the field of AI-driven precision medicine, made headlines recently by filing an application with the New York State Department of Health (NYSDOH) for the authorization of its Caris Assure® blood-based molecular profiling test. The clinical testing of this innovative approach hinges on meeting the rigorous standards set forth by the Clinical Laboratory Evaluation Program (CLEP) governed by the Wadsworth Center.

What is Caris Assure?

The Caris Assure test is cutting-edge, utilizing a minimally invasive blood sample to conduct a thorough biomarker analysis. It employs circulating nucleic acids sequencing (cNAS) methods to evaluate the whole exome and whole transcriptome of over 22,000 genes. This comprehensive profiling enables the identification of various critical factors, including tumor alterations, clonal hematopoiesis, inherited variants, and pharmacogenomic changes, alongside assessing microsatellite instability (MSI) and tumor mutational burden (TMB).

The test aims to enhance treatment strategies by providing essential genomic data that can pave the way for personalized therapy selections, potentially improving patient outcomes significantly.

The Review Process

Submitting this application marks the commencement of a formal review process mandated by New York State for laboratories wishing to execute testing on specimens sourced from New York patients. The Wadsworth Center conducts meticulous assessments that include evaluating laboratory permits, validating laboratory-developed tests, and ensuring compliance with existing state regulations.

David Spetzler, President of Caris Life Sciences, stated, "Caris is committed to meeting the highest standards for laboratory quality, validation, and regulatory compliance. This submission reflects our disciplined approach to expanding access to our technologies in a way that demonstrates the rigor, responsibility, and patient focus that define Caris Life Sciences."

While the application process unfolds, it’s crucial to note that no decision has yet been made by NYSDOH regarding the authorization of Caris Assure for use on blood-based specimens. Until CLEP grants the necessary authorization, the test cannot be offered for use in New York.

Caris Life Sciences: A Leader in Precision Medicine

Caris Life Sciences operates a CAP-accredited and CLIA-certified laboratory, conducting tests in jurisdictions where it is permitted, adhering to all relevant federal, state, and local regulations. The success of Caris Assure in New York will depend on the successful completion of the CLEP review process and acquiring necessary approvals.

Founded with the vision of unlocking the potential of precision medicine, Caris is continuously developing and commercializing innovative solutions to reshape how healthcare is delivered. With an emphasis on comprehensive molecular profiling and the implementation of next-gen AI technologies, Caris is establishing a large-scale clinico-genomic database designed to delve into the molecular intricacies of disease.

Headquartered in Irving, Texas, Caris has expanded its footprint internationally, maintaining offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland, thereby broadening its reach in delivering precise medical solutions across the globe.

As the field of oncology progresses rapidly, tests like Caris Assure symbolize a significant step forward in personalized medicine. For healthcare providers and patients in New York, the potential availability of this advanced testing could herald a new era in cancer treatment and management.

In conclusion, Caris Life Sciences' submission to the New York State Department of Health highlights its unwavering commitment to enhancing healthcare through innovation and rigorous compliance, aiming to provide timely and critical genomic information to clinicians everywhere.